Affimed NVNASDAQ:AFMD
- LAST PRICE3.4800
- TODAY'S CHANGE (%)-0.1700 (-4.6575%)
- Bid / Lots3.4800/ 10
- Ask / Lots3.8000/ 2
- Open / Previous Close3.6600 / 3.6500
- Day Range
- 52 Week Range
- Volume132,609
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AFMD |
|---|---|---|
| 09:32 ET | 359 | 3.66 |
| 09:33 ET | 1400 | 3.7315 |
| 09:37 ET | 268 | 3.76 |
| 09:39 ET | 265 | 3.75461 |
| 09:42 ET | 1200 | 3.72 |
| 09:46 ET | 6808 | 3.64 |
| 09:48 ET | 200 | 3.65 |
| 09:50 ET | 600 | 3.66 |
| 09:51 ET | 1500 | 3.7 |
| 09:53 ET | 690 | 3.6879 |
| 09:55 ET | 3000 | 3.66 |
| 10:02 ET | 1451 | 3.64 |
| 10:08 ET | 1556 | 3.68 |
| 10:09 ET | 2178 | 3.7 |
| 10:15 ET | 700 | 3.69 |
| 10:18 ET | 653 | 3.685 |
| 10:20 ET | 10500 | 3.7 |
| 10:31 ET | 2990 | 3.66 |
| 10:38 ET | 986 | 3.63 |
| 10:45 ET | 100 | 3.64 |
| 10:49 ET | 800 | 3.63 |
| 10:54 ET | 4712 | 3.56 |
| 10:56 ET | 200 | 3.6 |
| 10:58 ET | 1800 | 3.565 |
| 11:00 ET | 600 | 3.58 |
| 11:03 ET | 300 | 3.58 |
| 11:05 ET | 3000 | 3.5832 |
| 11:07 ET | 200 | 3.6 |
| 11:12 ET | 3000 | 3.6 |
| 11:20 ET | 500 | 3.58 |
| 11:23 ET | 200 | 3.5801 |
| 11:38 ET | 800 | 3.6 |
| 11:54 ET | 100 | 3.6295 |
| 11:59 ET | 600 | 3.605 |
| 12:01 ET | 1300 | 3.58 |
| 12:03 ET | 400 | 3.58 |
| 12:06 ET | 100 | 3.58 |
| 12:08 ET | 4200 | 3.57 |
| 12:12 ET | 1237 | 3.55 |
| 12:15 ET | 4000 | 3.540367 |
| 12:17 ET | 300 | 3.55 |
| 12:19 ET | 500 | 3.575 |
| 12:28 ET | 100 | 3.58 |
| 12:35 ET | 2384 | 3.56 |
| 12:37 ET | 660 | 3.575 |
| 12:44 ET | 220 | 3.569788 |
| 12:50 ET | 100 | 3.57 |
| 12:51 ET | 100 | 3.57 |
| 01:00 ET | 167 | 3.58 |
| 01:09 ET | 100 | 3.58 |
| 01:15 ET | 665 | 3.56 |
| 01:18 ET | 870 | 3.56 |
| 01:20 ET | 2325 | 3.56 |
| 01:24 ET | 200 | 3.56 |
| 01:36 ET | 300 | 3.55 |
| 01:44 ET | 100 | 3.53 |
| 01:49 ET | 100 | 3.54 |
| 01:56 ET | 1400 | 3.53 |
| 01:58 ET | 100 | 3.51 |
| 02:02 ET | 812 | 3.495 |
| 02:03 ET | 100 | 3.49 |
| 02:05 ET | 498 | 3.5091 |
| 02:09 ET | 233 | 3.4778 |
| 02:18 ET | 200 | 3.51 |
| 02:20 ET | 598 | 3.505 |
| 02:21 ET | 100 | 3.505 |
| 02:23 ET | 2099 | 3.475 |
| 02:30 ET | 300 | 3.48 |
| 02:32 ET | 100 | 3.485 |
| 02:34 ET | 100 | 3.485 |
| 02:38 ET | 100 | 3.49 |
| 02:43 ET | 1474 | 3.48 |
| 03:35 ET | 1123 | 3.49 |
| 03:37 ET | 400 | 3.495 |
| 03:39 ET | 2500 | 3.515 |
| 03:44 ET | 100 | 3.52 |
| 03:48 ET | 100 | 3.51 |
| 03:50 ET | 100 | 3.51 |
| 03:51 ET | 3501 | 3.48 |
| 03:53 ET | 817 | 3.48 |
| 03:55 ET | 6535 | 3.505 |
| 03:57 ET | 500 | 3.48 |
| 04:00 ET | 20091 | 3.48 |
Nov 15, 2024
DJ Affimed Is Maintained at Hold by Stifel, from 8:20AM ET on Friday Nov 15, 2024 by Dow Jones
8:20AM ET on Friday Nov 15, 2024 by Dow JonesDJ Affimed Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 7:38AM ET on Friday Nov 15, 2024 by Dow Jones
7:38AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
Affimed Reports Third Quarter 2024 Financial Results & Business Update, from 6:30AM ET on Thursday Nov 14, 2024 by Dow Jones
6:30AM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: Affimed Reports Third Quarter 2024 Financial Results & Business Update, from 6:30AM ET on Thursday Nov 14, 2024 by Dow Jones
6:30AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 6, 2024
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024, from 6:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
6:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Affimed NV | 53.0M | -0.6x | --- |
Atara Biotherapeutics Inc | 68.0M | -0.5x | --- |
Collplant Biotechnologies Ltd | 48.0M | -2.7x | --- |
Kronos Bio Inc | 51.3M | -0.5x | --- |
Clearside Biomedical Inc | 74.0M | -2.2x | --- |
Curis Inc | 32.8M | -0.5x | --- |
Company Information
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Contact Information
- Headquarters
- Im Neuenheimer Feld 582HEIDELBERG, Germany 69120
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Supervisory Board
- Thomas Hecht
- Chief Executive Officer, Member of the Management Board
- Shawn Leland
- Consulting Chief Financial Officer, Member of the Management Board
- Harry Welten
- Chief Operating Officer, Member of the Management Board
- Wolfgang Fischer
- Chief Medical Officer, Member of the Management Board
- Andreas Harstrick
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $53.0M |
|---|---|
Revenue (TTM) | $2.8M |
Shares Outstanding | 15.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.12 |
EPS | $-5.54 |
Book Value | $4.08 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 18.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,012.15% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
